key: cord-0993999-txt0jj45 authors: Mohanty, R. R.; Meher, B. R.; Padhy, B. M.; Das, S. title: Repurposing Colchicine for the management of COVID-19: A systematic review and meta-analysis date: 2021-02-19 journal: nan DOI: 10.1101/2021.02.17.21251884 sha: 56e96f123202248dd40d701f875ec1bfdcf4cebb doc_id: 993999 cord_uid: txt0jj45 Many anti-inflammatory drugs (including tocilizumab, N-acetylcysteine, and itolizumab) have been repurposed for the management of COVID 19, with variable levels of success. Colchicine achieves anti inflammatory activity through tubulin disruption and the inhibition of leucocyte mediated inflammatory activities (such as the production of superoxide and release of various cytokines), which are central to the pathophysiology of COVID 19. Accordingly, this systematic review and meta analysis provides an assessment of currently available data pertaining to the use of colchicine for the treatment of COVID 19. Three studies (two RCTS and one observational) were included in the review, totaling 402 patients of whom 194 received colchicine. The random effect model showed the overall pooled OR to be 0.32 (95% CI: 0.18 to 0.56) for the primary outcome (clinical deterioration), which was statistically significant (p < 0.0001). Further, there was an increase in adverse effects (diarrhea) with the use of colchicine, as suggested by the pooled OR (OR = 4.56, 95% CI: 2.04 to 10.15, P = 0.0002). Despite the limited number of available studies, a statistically significant reduction of clinical deterioration in COVID 19 patients was revealed. However, there was an increase in adverse effects in the form of diarrhea, which was mild and self limiting. Author contribution and approval: The development of the concept and the preliminary search was carried out by RRM and BMP. Extensive database search, data extraction, and quality assessment were carried out by RRM, SM, and BRM. Any disagreement was resolved by BMP. All the data synthesis and statistical analysis were done by BRM, BMP, and RRM. The manuscript was written by RRM, BRM, BMP, and SD. The final version for publication was approved by all the authors. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 19, 2021. ; https://doi.org/10.1101/2021.02.17.21251884 doi: medRxiv preprint 4 Title: Repurposing Colchicine for the management of COVID-19: A systematic review and meta-analysis. Since its inception in November 2019, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a pandemic affecting more than 195 countries with approximately 31 million infections and 0.97 million deaths till the end of September 2020 [1] .Though viral pneumonia is the common clinical presentation, the major complication of coronavirus disease 2019 (COVID-19) is due to immune activation, hyper inflammatory state, prothrombotic state, and cytokine storm [2, 3] . All these pathologic processes leads to acute respiratory distress syndrome (ARDS), which is a life-threatening form of acute lung injury [4] . The inflammatory mediators responsible for cytokine storm and ARDS, like interleukin 1 (IL1), interleukin 6 (IL6), and tumor necrosis factors (TNFs) have been found to increase in severe COVID-19 [5] . Therefore, many anti-inflammatory drugs like tocilizumab, N-acetylcystiene, and etolizumab have been repurposed for management of COVID-19 with variable success [6] [7] [8] . Colchicine is a lipid-soluble alkaloid derived from Colchicum autumnale [9] . Currently it is being used for many auto-inflammatory conditions like gout, Behcet's disease, and familial Mediterranean fever [10] . Tubulin disruption and subsequent down regulation of inflammatory pathway is the major mechanism of action of colchicine [11] . An in vitro study has demonstrated that the internalization of the coronavirus is dependent on tubulin function [12] . Also colchicine inhibits leucocyte-mediated inflammatory activities like the production . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted February 19, 2021. ; https://doi.org/10.1101/2021.02.17.21251884 doi: medRxiv preprint of superoxide and release of various cytokines [13] . Based on these anti-inflammatory properties of colchicine, researchers have proposed its use in COVID-19 [14, 15] . A case report by Mansouri et al, demonstrated the beneficial effect of colchicine in COVID-19 associated cytokine release syndrome [16] . Similarly a case series of 9 patients reported the favourable outcome by colchicine use in COVID-19 [17] . Additionally, few randomized controlled trials (RCTs) and observational studies have also been carried out to assess the clinical efficacy of colchicine in the management of COVID-19 [18-20]. Hence, we conducted this systematic review and meta-analysis to assess the currently available data to rationalize the repurposing of colchicine for the treatment of COVID 19 as add on therapy. This review may provide clinicians an overview of contemporary scientific evidence regarding the use of colchicine in the management of COVID 19 patients. The protocol was written in accordance with PRISMA-P guideline and registered in the prospective register of a systematic review (PROSPERO). The PROSPERO registration number is CRD42020209814. All RCTs and observational studies comparing the use of colchicine in COVID 19 with usual care or placebo were included for the analysis. Clinical outcome and adverse effects were the outcome measures in all the included studies. The study inclusion was not restricted by year of publication, site of study, and dose of colchicine used. The studies published only in the English language were included. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) RT-PCR confirmed COVID-19 adult patients of both genders treated with usual care with or without the addition of colchicine were included in the study. The intervention was defined as the administration of colchicine in COVID 19 patients along with usual care irrespective of the dose, timing, or frequency. The comparison was between usual care with colchicine versus usual care alone or with a placebo. Primary outcome: 1. Clinical deterioration (within the follow up time available in each study). Clinical deterioration was defined as the need for oxygen supplementation or ICU care or death Secondary outcomes: The adverse effect was defined as the development of diarrhoea (as it is the most common adverse effect of colchicine) and/or any other adverse effect leading to the withdrawal of colchicine. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 19, 2021. ; https://doi.org/10.1101/2021.02.17.21251884 doi: medRxiv preprint 7 Information source: PubMed, EMBASE, the Cochrane Library, SCOPUS, and Web of Science were searched for articles on colchicine therapy in COVID 19 from inception till September 15, 2020. The reference lists of retrieved articles were checked for additional studies. For unpublished data, we checked the International Clinical Trials Registry Platform (ICTRP), which is a central database containing trial registration data sets provided by the different international trial registries including ClinicalTrials.gov. Pre-print server medRxiv and bioRxiv were also searched for pre-print data. A combination of subject terms and keywords were used and appropriate adjustments of vocabulary and grammar between different databases were done using the PICO method. The search used both Medical Subject Headings (MeSH), as well as keyword variants of all relevant terms. A combination of keywords and Boolean operators like "Colchicine" OR "Anti-inflammatory drug" AND "COVID-19" OR "Severe acute respiratory syndrome coronavirus 2" was used for designing the search algorithm. Three review authors (RRM, BRM, SD) independently extracted and assessed the quality of data using the predefined eligibility criteria following Cochrane Collaboration's guidelines. Any disagreement between them was resolved by the fourth author (BMP). A pre-designed data extraction format was used for the recording of data which includes study design, basic information, treatment details, and outcome measures. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) Risk of bias-2 (RoB-2) tool for RCTs and Risk of Bias in Non-Randomized Studies -of Interventions (ROBINS-I) for the observational study were used to assess the risk of bias. Cochrane Program Review Manager 5.3 software was used for the Meta-analysis. For dichotomous values, odd's ratio (OR) and 95% confidence interval was expressed in accordance with Cochrane Handbook for Systematic Reviews of Interventions. I 2 statistic was used to check heterogeneity among eligible studies. The random-effect model was used for data synthesis. A funnel plot was used to assess the presence of publication bias. GRADE profiler software (V 3.6.1) was used for quality assessment of the evidence. All database searches resulted in a total of 97 studies describing the use of colchicine in COVID-19. Fifty two studies from PubMed, 22 on-going registered clinical trials, and 23 studies from pre-print server medRxiv were retrieved. After reviewing abstracts and full text, 3 studies (2 RCTs and 1 observational study) were selected for systematic review and metaanalysis as per the inclusion criteria. The PRISMA flowchart of study selection is depicted in The risk of bias assessment for all studies was carried out for the primary outcome. The use of RoB-2 revealed that both the RCTs had "some concerns" regarding the risk of bias. In the observational study included in the meta-analysis, there was a "serious" risk of bias as per ROBINS-I. The result of the risk of bias assessment of RCTs and observational study is depicted in figure 2 . The pooled effect of adding colchicine to usual therapy on primary and secondary outcomes was measured. The forest plots for the pooled effect are depicted in figure 3. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 19, 2021. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) 1 1 Publication bias: Although we created a Funnel plot for publication bias, it could not be assessed as there were only 3 studies where the primary outcome was reported. However, due to the small sample size and large effect we expect that publication bias would be present. The evidence was assessed using GRADE profiler for clinical deterioration (primary outcome) and the development of adverse effects (secondary outcome). The grade of evidence was low for both the outcomes due to the risk of bias in the included studies and publication bias. The detailed analysis of the summary of evidence is depicted in table 3. To the best of our knowledge, this is the first systematic review and meta-analysis on the use of colchicine in the management of COVID-19. In the current study, 402 patients from 3 countries were included for estimating the pooled effect. There was a statistically significant reduction in clinical deterioration with the addition of colchicine to usual therapy as suggested by the pooled estimate (p< 0.0001), though the effect became statistically non- The role of colchicine in reducing D-dimer and inflammatory cytokine IL 6 were reported in many studies [16, 21] . The attenuation of the D-dimer rise was also reported in the GRECCO-19 trial [18] . It is worth mentioning that the rise in D-dimer plays a major role in developing various complications in COVID-19. It is well documented in previous studies that colchicine exhibit anti-inflammatory action without immunosuppression unlike corticosteroids and IL-6 inhibitors [19]. This action might be beneficial for a certain subset of COVID-19 patients with primary or secondary immunosuppression. The study has certain limitations. The number of included studies and the pooled sample size is less. Among them, one study is observational in nature and carries the risk of confounding and other biases. One of the RCTs included was open label and may have inherent assessment bias. The overall risk of bias in all studies ranged from some concern to serious . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) 1 3 and the quality of evidence is low. Additionally, there was variability in the follow up period between the studies ranging from 7 to 21 days. Colchicine is a safe, cost-effective, and potent anti-inflammatory medication without associated immunosuppression. Based on the limited number of available studies, the current meta-analysis shows a statistically significant reduction in clinical deterioration in COVID-19 patients with add on colchicine. Though there was an increase in adverse effects in the form of diarrhoea, it was mild and self-limiting. The clinical significance of repurposing colchicine for the management of COVID-19 will only emerge after larger RCTs with a greater sample size. The development of the concept and the preliminary search was carried out by RRM and BMP. Extensive database search, data extraction, and quality assessment were carried out by RRM, SM, and BRM. Any disagreement was resolved by BMP. All the data synthesis and statistical analysis were done by BRM, BMP, and RRM. The manuscript was written by RRM, BRM, BMP, and SD. The final version for publication was approved by all the authors. There are no conflicts of interest. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted February 19, 2021. ; https://doi.org/10.1101/2021.02.17.21251884 doi: medRxiv preprint WHO Coronavirus Disease (COVID-19) Dashboard Available at Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment Cytokine Storm in COVID-19-Immunopathological Mechanisms, Clinical Considerations, and Therapeutic Approaches: The REPROGRAM Consortium Position Paper The possible pathophysiology mechanism of cytokine storm in elderly adults with COVID-19 infection: the contribution of "inflame-aging Tackle the free radicals damage in COVID-19 Tocilizumab treatment in COVID-19: A single center experience Entry of Human Coronavirus NL63 into the Cell Entry of Human Coronavirus NL63 into the Cell Dapsone, colchicine and olanzapine as treatment adjuncts to prevent COVID-19 associated adult respiratory distress syndrome (ARDS) Colchicina: unaherramientaterapéuticapotencialfrente a COVID-19. Experienciaen 5 pacientes Epub ahead of print Successful Treatment of Covid-19 Associated Cytokine Release Syndrome with Colchicine. A Case Report and Review of Literature . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 19, 2021. ; https://doi.org/10.1101/2021.02.17.21251884 doi: medRxiv preprint . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 19, 2021. ; https://doi.org/10.1101/2021.02.17.21251884 doi: medRxiv preprint . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 19, 2021. ; https://doi.org/10.1101/2021.02.17.21251884 doi: medRxiv preprint . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)The copyright holder for this preprint this version posted February 19, 2021. ; https://doi.org/10.1101/2021.02.17.21251884 doi: medRxiv preprint